ArticleInfluenza and other respiratory viruses2025
A Framework for Evaluating the Use of Surveillance Systems for Short-Term Influenza Forecasting.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Framework for Evaluating the Use of Surveillance Systems for Short-Term Influenza Forecasting.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublic health surveillance systems need to monitor influenza activity and guide measures to mitigate its high impact on morbidity, mortality and healthcare systems. There is an increasing expectation that surveillance data will support the modeling of future short-term disease scenarios using artificial intelligence (AI) and machine learning (ML). This study examines how influenza surveillance can support AI/ML-based short-term forecasting for influenza at the community and hospital levels in a high-income country setting (Aotearoa/New Zealand).
methodsThis study used a two-phase approach. The first phase involved a comprehensive review of government reports, official websites, and literature to characterize existing influenza surveillance systems. The second phase evaluated systems against eight key attributes-timeliness, sensitivity, specificity, representativeness, coverage, robustness, completeness, and historical data-using a five-level ranking system. Attribute selection was informed by experts' knowledge, ML requirements, and established frameworks. Weighted scores for training and short-term forecasting capabilities were calculated to determine alignment with AI/ML requirements.
resultsThe Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) community cohort and Severe Acute Respiratory Infection (SARI) hospital surveillance emerged as the most useful systems, achieving the highest scores in both training and short-term forecasting in community and hospital settings, respectively. The National Minimum Dataset of hospitalizations and mortality datasets demonstrated strong training potential but are limited in short-term forecasting due to timeliness constraints. Additionally, laboratory-based surveillance performs a useful role in bridging community and hospital datasets.
conclusionsA set of key attributes is useful for assessing which influenza surveillance systems are best aligned with AI/ML training and short-term forecasting requirements. These attributes distinguished systems that are likely to be the most suitable for modeling future short-term disease scenarios for influenza at the community and hospital levels in New Zealand. Integrating these data sources could enhance influenza forecasts to improve public health responses and intervention planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.